Suppressing chemoresistance in lung cancer via dynamic phenotypic switching and intermittent therapy
Suppressing chemoresistance in lung cancer via dynamic phenotypic switching and intermittent therapy
A major challenge in cancer therapy is drug resistance, which is typically attributed to acquired mutations and tumor heterogeneity. However, emerging evidence suggests that dynamic cellular interactions and group behavior also contribute to drug resistance, although, the details of such mechanisms are poorly understood. Here, by combining real time cellular …